



## Biopharmapark Dessau Awarded “Site for the Future” Designation

Dessau-Roßlau, 23 June 2023 – The future is being created at the Biopharmapark in Dessau-Roßlau. The companies located here, including IDT Biologika, Merz, Oncotec, Ceva, have a high level of expertise in pharmaceutical manufacturing and packaging as well as the research and development of innovative vaccines, cell and gene therapy products and biologics. For this know-how the pharma site was awarded of the distinction “Zukunftsort” - site for the future - by Saxony-Anhalt Secretary of State for Economic Affairs Stefanie Pöttsch and Dr. Robert Franke, CEO of the Investitions- und Marketinggesellschaft (IMG) at the career day.

Secretary of State for Economic Affairs Stefanie Pöttsch emphasized: “Biopharmapark Dessau is one of the key pharmaceutical and biotechnology locations in Saxony-Anhalt and Germany. It is characterized by the intensive cooperation between business and science. With its central location and over 100 years of tradition, the site also offers ample space in which firms can locate, as well as for further developments and new synergies. Together, all of these factors make it a site for the future worthy of the distinction.”

The 13 sites for the future in Saxony-Anhalt group together science, research and business. Here skilled workers can find numerous options for realizing their career goals and applying their expertise.

Dr. Robert Franke, CEO of IMG, explained: “Biopharmapark Dessau is one of the most important sites in the state for this sector and justifies its “site for the future” appellation. We use our site marketing to support the visibility of Biopharmapark Dessau beyond the region itself to potential investors and skilled personnel.”

With approximately 1,700 employees, IDT Biologika is the largest company in the Biopharmapark. The venerable Dessau-based company can look back on a 100-year history and has evolved dynamically in recent years with the contract manufacturing and development of premium human vaccines, cell and gene therapy products and biologics. During the covid pandemic IDT Biologika provided urgently required capacity for the filling and packing of COVID-19 vaccines, making a key contribution to society.

Dr. Jürgen Betzing, CEO IDT Biologika, underlined: “We are proud that the Biopharmapark is a site for the future.” Here employees can find the perfect environment in which to pursue their careers and develop their skills. We support our staff in all aspects of their lives, enabling them to reconcile work, leisure time and family in an optimal manner. We are highly appreciative of the initiatives of the state of Saxony-Anhalt to attract skilled workers. Because it is only with qualified personnel, undertaking their tasks and projects with enthusiasm, that we can offer our customers a high level of service and help to mold the future of Saxony-Anhalt as a pharmaceuticals location.”

To meet the increased demand for vaccines and biopharmaceutical products, in recent years IDT has invested in workplaces, technology and plant, as well as new premises for the manufacture of drug substances, aseptic liquid filling, packaging options and automated visual inspection. IDT Biologika



therefore continues to play an important role in the provision of healthcare, not only by supplying vital medicines, but also in the event of a pandemic. The German federal government has included IDT Biologika as one of five companies in the pandemic preparedness program.

On a tour of the “site for the future,” Stefanie Pöttsch and Dr. Robert Franke inspected the drug substance production area, which was extended this year.

Following the award event, Stefanie Pöttsch opened the careers fair. The companies (IMG Investitions- und Marketinggesellschaft Sachsen-Anhalt, Ceva, Oncotec, Merz, Octapharma, IDT Biologika, TEW Technik-Energie-Wasser-Servicegesellschaft, Bundesagentur für Arbeit, Stadt Dessau-Roßlau) provided information to trainees, skilled workers and career changers and offered tours of various departments.

#### Further information:

Investitions- und Marketinggesellschaft, sites for the future campaign: <https://www.zukunftsorte-sachsen-anhalt.de/biopharmapark-dessau>

Website of the Biopharmapark: <https://tew-service.de/>

Website of IDT Biologika: <https://idt-biologika.de/>

4.055 characters (including spaces)

#### Image material



[2023-06-23 Urkundenübergabe.jpg]

Caption: Dr. Robert Franke IMG CEO and Secretary of State for Economic Affairs Stefanie Pöttsch hand Frank Föhri, CEO TEW, the certificate for the “site for the future” Biopharmapark



f.l.t.r. Melanie Bley (IDT), Dr. Thekla Kurz (Ceva), Dr. Robert Franke (IMG), Frank Föhrigen (TEW), Stefanie Pöttsch (Secretary of State for Economic Affairs), Susann Hartung (Felgenträger), Christin Richter (Oncotec), Björn Niemczak (Merz)



[2023-06-23 Rundgang IDT Biologika.jpg]

Caption: Secretary of State for Economic Affairs Stefanie Pöttsch and Dr. Robert Franke, IMG CEO, tour the drug substance production operations of IDT Biologika

f.l.t.r. Dr. Andrea Schänzler (IDT), Sabine Kraus (IMG), Stefanie Pöttsch (Secretary of State for Economic Affairs), Frank Föhrigen (TEW), Dr. Robert Franke (IMG)

## About IDT Biologika

IDT Biologika is an innovative biotech company with a successful history dating back 100 years. Based on modern technologies and high levels of expertise, IDT supports customers in the development and manufacture of innovative virus vaccines, gene and immune therapy products as well as biologics



employed worldwide as protection against diseases. German sites are the BioPharmaPark in Dessau-Roßlau and Magdeburg. In the US, the IDT Corporation has a manufacturing site for clinical test samples in Rockville, Maryland.

**Website:** [www.idt-biologika.com](http://www.idt-biologika.com)

**Contact IDT Biologika**

Corinna Meisel

Corporate Communications

M +49 (0)173 9249671

[corinna.meisel@idt-biologika.de](mailto:corinna.meisel@idt-biologika.de)

IDT Biologika GmbH | Am Pharmapark | D-06861 Dessau-Roßlau, Germany